ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes exoskeletons for wheelchair-bound individuals with mobility impairments or other medical conditions. The company offers ReWalk Personal for everyday use to paraplegic individuals at home and in their communities; and ReWalk Rehabilitation for exercise and therapy used in hospitals and rehabilitation centers in the United States and Europe. It is also developing ReWalk Restore, a soft suit exoskeleton for individuals who have suffered a stroke. ReWalk Robotics Ltd. markets and sells its products directly to third party payers, institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was founded in 2001 and is headquartered in Yokne'am Illit, Israel.
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Phone972-4959-0123
Debt
Current Ratio0.91
Quick Ratio0.69
Price-To-Earnings
Sales & Book Value
Annual Sales$7.75 million
Price / Sales0.97
Price / Cash FlowN/A
Price / Book1.62
Profitability
Net Income$-24,710,000.00
Net Margins-352.11%
Return on Assets-119.11%
Miscellaneous
Employees65
OptionableNot Optionable
Rewalk Robotics (NASDAQ:RWLK) Frequently Asked Questions
What is Rewalk Robotics' stock symbol?
Rewalk Robotics trades on the NASDAQ under the ticker symbol "RWLK."
How were Rewalk Robotics' earnings last quarter?
Rewalk Robotics Ltd (NASDAQ:RWLK) released its earnings results on Thursday, November, 8th. The medical device company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.01. The medical device company earned $1.62 million during the quarter, compared to analyst estimates of $2.12 million. Rewalk Robotics had a negative return on equity of 3,654.32% and a negative net margin of 352.11%. View Rewalk Robotics' Earnings History.
When is Rewalk Robotics' next earnings date?
What guidance has Rewalk Robotics issued on next quarter's earnings?
Rewalk Robotics updated its FY 2018 earnings guidance on Thursday, November, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $7-8 million, compared to the consensus revenue estimate of $8.21 million.
What price target have analysts set for RWLK?
3 Wall Street analysts have issued 12 month price targets for Rewalk Robotics' stock. Their forecasts range from $1.00 to $2.00. On average, they expect Rewalk Robotics' share price to reach $1.6667 in the next twelve months. This suggests a possible upside of 693.7% from the stock's current price. View Analyst Price Targets for Rewalk Robotics.
What is the consensus analysts' recommendation for Rewalk Robotics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rewalk Robotics in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Rewalk Robotics.
What are Wall Street analysts saying about Rewalk Robotics stock?
Here are some recent quotes from research analysts about Rewalk Robotics stock:
- 1. According to Zacks Investment Research, "ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. The Company's exoskeletons allow wheelchair-bound individuals with mobility impairments or other medical conditions the ability to stand and walk once again. It offers ReWalk Personal for everyday use to individuals at home and in their communities; and ReWalk Rehabilitation for exercise and therapy to individuals with lower limb disabilities in the clinical rehabilitation environment. ReWalk Robotics Ltd. is headquartered in Yokneam Ilit, Israel. " (10/25/2018)
- 2. Canaccord Genuity analysts commented, "We maintain our BUY rating on ReWalk Robotics following Q4/17 results. ReWalk reported revenues of $1.5M, below CG/consensus of $2.1M/$1.9M. Although the shipment of 23 systems was well below our expectation for 42 systems, ReWalk sales benefited from a favorable mix of system purchases and rental conversions in the quarter. Despite the weaker than anticipated system placements, we were encouraged to see another quarter of strong demand and another positive coverage decision with reimbursement through Italy’s worker’s compensation group. While commercial unit placements continue to be lumpy Q/Q we continue to view the broader pipeline (Restore soft suit for stroke) positively in the H2/18 and beyond. Positive momentum in demand and reimbursement decisions: In Q4/17 the company placed 23 total units, down from 39 Y/Y but up Q/Q from 16." (3/12/2018)
Has Rewalk Robotics been receiving favorable news coverage?
News coverage about RWLK stock has been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Rewalk Robotics earned a news impact score of -1.2 on InfoTrie's scale. They also gave news coverage about the medical device company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the next several days.
Are investors shorting Rewalk Robotics?
Rewalk Robotics saw a decrease in short interest during the month of December. As of December 31st, there was short interest totalling 549,386 shares, a decrease of 44.7% from the December 14th total of 993,726 shares. Based on an average trading volume of 2,210,903 shares, the days-to-cover ratio is currently 0.2 days. Currently, 1.2% of the shares of the company are sold short. View Rewalk Robotics' Current Options Chain.
Who are some of Rewalk Robotics' key competitors?
Who are Rewalk Robotics' key executives?
Rewalk Robotics' management team includes the folowing people:
- Mr. Lawrence J. Jasinski, CEO & Director (Age 62)
- Mr. Ofir Koren, GM and VP of Research, Devel. & Regulatory (Age 49)
- Mr. Ori Gon, Chief Financial Officer (Age 37)
- Ms. Miri Pariente, VP of QA & Operations (Age 42)
- Mr. Loren Wass, VP of Sales & Reimbursement
How do I buy shares of Rewalk Robotics?
Shares of RWLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Rewalk Robotics' stock price today?
One share of RWLK stock can currently be purchased for approximately $0.21.
How big of a company is Rewalk Robotics?
Rewalk Robotics has a market capitalization of $7.94 million and generates $7.75 million in revenue each year. The medical device company earns $-24,710,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. Rewalk Robotics employs 65 workers across the globe.
What is Rewalk Robotics' official website?
How can I contact Rewalk Robotics?
Rewalk Robotics' mailing address is 3 Hatnufa Street Floor 6, Yokneam Ilit L3, 2069203. The medical device company can be reached via phone at 972-4959-0123.
MarketBeat Community Rating for Rewalk Robotics (NASDAQ RWLK)
MarketBeat's community ratings are surveys of what our community members think about Rewalk Robotics and other stocks. Vote "Outperform" if you believe RWLK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RWLK will underperform the S&P 500 over the long term. You may vote once every thirty days.
